Cancer Precision Medicine Is Changing How Patients Choose Personalized, Whole-Journey Care
When two patients with the same type of cancer sit in a clinic, they may not be facing the same disease. Tumor gene alterations, the immune microenvironment, stage, prior treatments, liver and kidney function, and physical condition can all differ. So can drug response and the risk of side effects. That is why cancer precision medicine is gaining importance. Treatment is no longer only about asking, “What drug is usually used for this cancer?” It is also about asking, “What approach is most likely to help this patient now, and how can treatment be completed safely?”
For patients and families, precision medicine is not just one genetic test or one lab report. It is a care process that includes assessment, treatment selection, symptom support, response monitoring, and recovery follow-up. The goal is not only to control the tumor, but also to maintain strength and quality of life, so that patients have clearer choices at every stage.
Why Cancer Precision Medicine Is Moving From “Finding a Drug” to Whole-Person Care
Early discussions of precision medicine often focused on whether tumor genetic testing could identify a usable targeted drug. That remains an important core. In some lung, breast, colorectal, ovarian, and blood cancers, specific biomarkers may support targeted therapy, immunotherapy, antibody-drug conjugates, or other personalized strategies.
But a test result does not automatically equal the right treatment. Even when a gene alteration is found, clinicians still need to ask whether there is enough clinical evidence, whether the drug is appropriate for that tumor type, whether the patient can tolerate the side effects, and whether the treatment goal is cure, disease control, or symptom relief. If testing does not find an actionable target, that does not mean there is no treatment path. Standard chemotherapy, radiotherapy, surgery, or immunotherapy may still be the more suitable option.
In recent years, the direction has been to interpret tumor data in the context of the patient’s overall health. Malnutrition, anemia, infection risk, sleep problems, anxiety, muscle loss, and poorly controlled chronic disease can all affect whether a patient can complete treatment as planned. Precision should not apply only to the drug. It should also apply to the conditions that help a patient finish treatment.
From Tissue Testing to Liquid Biopsy: Information Is More Dynamic, and More Interpretation Is Needed
Tissue testing remains an important foundation for diagnosis and treatment planning in many cancers. Pathology can confirm tumor type, while molecular testing can further analyze gene alterations, protein expression, or other biomarkers to help determine whether certain treatments are suitable.
Liquid biopsy uses signals in the blood, such as circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), to provide complementary information with less invasiveness. It may be useful when repeat tissue sampling is difficult, the tumor is in a deep location, or clinicians need to understand molecular changes after treatment. It may also capture information from different tumor sites and help observe how the cancer is evolving.
What CTCs Are, and How They Differ From ctDNA
Circulating tumor cells (CTCs) are intact cancer cells that have shed from a primary tumor or a metastatic site into the bloodstream. They are part of the process of cancer spread, but they are extremely rare in blood. Finding them is like searching for a few cells among a vast number of normal blood cells.
CTCs and ctDNA provide different kinds of information:
– ctDNA is mainly DNA fragments released after tumor cells die. It is useful for detecting gene mutations, tracking molecular changes, and, in some situations, assessing treatment response or residual disease.
– CTCs are intact cells. In addition to being counted, they retain cell morphology, protein expression, and some functional information. This can add a layer that gene fragments alone cannot show.
In some metastatic breast, prostate, and colorectal cancers, CTC numbers are linked to prognosis and can also serve as a supporting marker for dynamic monitoring. Reading CTCs together with ctDNA can give a fuller picture of tumor heterogeneity, changes after treatment, and some clues to drug resistance.
What makes CTCs especially valuable is that they do more than reveal a tumor signal. They can also support functional testing. Because CTCs are the patient’s own intact tumor cells, some platforms can perform drug-sensitivity analysis after isolation. Common chemotherapy drugs, selected targeted agents, and chosen natural substances or plant-based compounds can be tested against these cells to see which interventions more strongly suppress cell activity. For patients and families, this moves precision medicine from “what is commonly used for this cancer” to “what this patient’s cells appear more responsive to right now.”
This is especially helpful across the whole care journey. When tissue is hard to obtain again, when there are several treatment options, or when previous regimens have not worked as hoped, chemosensitivity results can offer a more personal reference for the next discussion. At the same time, many patients want to add nutritional support, natural substances, or other complementary components, but find the choices overwhelming. CTC testing can first identify substances that show stronger inhibitory activity against the patient’s own cells. Supportive care can then be planned according to individual cellular response, rather than by general experience or online information alone.
In vitro results still need to be interpreted in the context of the whole clinical picture, including stage, organ function, current medicines, nutritional status, and life goals. The range of drugs and natural substances that can be tested also depends on the platform and on whether enough CTCs can be isolated from the blood. The most reliable approach is for the care team to explain the purpose of testing, how the report will inform treatment and supportive care, and what should be decided under oncology supervision. Patients should not add or stop medicines or supplements on their own. Used this way, CTC testing can become a bridge between anticancer treatment and personalized support, rather than a standalone lab report.
Likewise, liquid biopsy does not need to replace tissue testing in every situation. At the right moment, it can provide repeatable, less invasive complementary information. What patients need most is not simply “more tests,” but a clear explanation of why a test is being done, how the result can help decision-making, and how CTCs and ctDNA can complement each other.
Immunotherapy Choices Cannot Rest on a Single Marker
Immunotherapy has opened new opportunities for some patients, but not everyone responds in the same way. PD-L1 expression, microsatellite instability, tumor mutational burden, cancer type, speed of disease progression, and previous medicines may all affect the decision. A higher marker does not guarantee benefit. Conversely, some patients with less prominent markers may still benefit in selected clinical situations.
Immune-related side effects are another consideration that is easy to overlook. Immunotherapy may affect the skin, gut, lungs, liver, thyroid, or other organs. Patients with autoimmune disease, interstitial lung disease, or organ-function problems need especially careful assessment before treatment, and early attention to new symptoms during treatment. The value of precision medicine is in balancing potential benefit with individual risk, not in treating every new therapy as the only answer.
Supportive Care Is Part of the Treatment Plan, Not an Extra Option Outside It
Cancer treatment often brings fatigue, reduced appetite, nausea, sleep disturbance, peripheral nerve discomfort, or lowered immunity. If these problems accumulate, patients may need delayed cycles, dose reductions, or may lose their usual rhythm of life. Early assessment and management can preserve more room for later treatment.
Personalized support should be based on clinical condition and test results. Anemia, for example, needs to be distinguished according to whether it is related to iron deficiency, chronic inflammation, bone-marrow suppression, bleeding, or kidney function. Fatigue may be linked to inadequate nutrition, infection, thyroid function, sleep, or mood. Whether intravenous iron, nutrition infusions, amino-acid support, or other supportive arrangements are suitable should be reviewed by a doctor according to the illness, current cancer drugs, and organ function. A single symptom should not be used as the only basis for self-directed treatment.
If a patient also has CTC chemosensitivity or natural-substance testing results, those reports should be brought back to the primary oncology team for joint discussion. The role of integrative oncology care is to help maintain nutrition, physical capacity, and recovery without interfering with the main anticancer treatment. All supplements, herbal products, infusion therapies, and other supportive plans should be disclosed to the oncologist, to reduce the risk of interactions with chemotherapy, targeted drugs, anticoagulants, or immunotherapy.
Precision Care Should Also Look After Long-Term Health After Treatment
Completing the main course of treatment does not mean care is finished. Some patients need ongoing monitoring for recurrence risk, management of the effects of hormone therapy or long-term medicines, and attention to bone health, cardiovascular risk, metabolic health, cognition, and emotional stress. People who have received certain chemotherapies or targeted treatments may need closer attention to heart function. Clear changes in weight, blood sugar, or sleep are also worth addressing early.
This is why precision medicine is gradually extending into prevention and recovery. A follow-up plan should not consist only of imaging dates. It can also include personalized nutrition assessment, exercise capacity, sleep, stress, and chronic-disease markers. For families, understanding the support a patient truly needs can sometimes reduce anxiety more than continually searching for a new therapy.
Questions Patients Can Ask Before Testing and Treatment Decisions
Before considering genetic testing, liquid biopsy, CTC drug-sensitivity testing, or a new treatment, patients can first confirm a few key questions with their doctor: What clinical question is this test meant to answer? How might the result change the current plan? If the result is negative, if cell numbers are insufficient, or if no target is found, what comes next? Are CTCs or ctDNA being used at this moment to support monitoring, complement tissue information, or are they not needed yet? If the test includes chemosensitivity or natural-substance analysis, which drugs and compounds will be covered, how should the in vitro results be read, and how might they help plan current treatment and supportive care? What are the main goals, expected benefits, and common risks of treatment? Could existing problems with fatigue, nutrition, or chronic disease affect the ability to complete treatment?
Asking clearly is not a challenge to medical decisions. It is a way for patients to take part in their own care. Patients in Hong Kong often face opinions from different specialties and a large amount of online information at the same time. What they need is a personalized plan that can integrate pathology reports, treatment records, physical condition, and daily-life needs. Under medical supervision, BMS Clinic can help patients sort out supportive needs and work with the primary oncology team to design care that focuses on recovery, immune support, and quality of life.
The most hopeful part of precision medicine is not a promise that every patient will receive the same breakthrough therapy. It is that each test, each treatment, and each period of recovery can come closer to what the patient truly needs. When scientific evidence and ongoing support travel together, patients can find more direction and strength on a treatment path that is full of uncertainty.